Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of invasive cervical cancer * Measurable disease * 0-1 prior chemotherapy regimens for recurrent or advanced disease; platinum based chemotherapy administered as a radiation sensitizer agent is allowed and does not count as prior therapy * Absolute granulocyte count (AGC) \>= 1,500 * Platelet \>= 100,000 * Serum creatinine \< 2.0 mg/dl * Bilirubin =\< 1.5 times the upper limit of the normal range (ULN) * Alkaline phosphatase =\< 3 x ULN (in the case of liver metastases, =\< 5 x ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN (in the case of liver metastases, =\< 5 x ULN) * Peripheral neuropathy grade 0-2 * Recovery of all chemotherapy or radiation-related toxicities to grade =\< 1, except for alopecia and peripheral neuropathy * Performance status 0-2 * Signed informed consent Exclusion Criteria: * Prior treatment with eribulin * Chemotherapy, radiation, or biological or targeted therapy within 3 weeks * Hormonal therapy within 1 week * Any investigational drug within 4 weeks * Known brain metastases, unless previously treated and asymptomatic for 3 months and not progressive in size or number for 3 months